Celltrion said on the 13th that it recently launched the autoimmune disease treatment Avtozma (ingredient name tocilizumab) in the United States. It can treat rheumatoid arthritis, giant cell arteritis, and systemic juvenile idiopathic arthritis, among others.
The product launched this time is an intravenous injection formulation. The company also plans to launch a subcutaneous injection formulation. Avtozma will be sold directly by the local subsidiary at a price 35% lower than the original drug.
Thomas Nusbickel, chief commercial officer (CCO) of Celltrion USA, said, "We will improve patients' access to care and their quality of life."
※ This article has been translated by AI. Share your feedback here.